好色先生

好色先生

Explore the latest content from across our publications

Log In

Forgot Password?
Create New Account

Loading... please wait

Abstract Details

APOE and 好色先生: Effects on Regional Tau and FDG Metabolism in Older Adults
Aging, Dementia, and Behavioral Neurology
S34 - Aging and Dementia: Risk Factors, Biomarkers, and Neuropathology (1:55 PM-2:06 PM)
006

Given that APOE ?4 and education have opposing influences on the onset of cognitive impairment and both strongly influence FDG metabolism in the elderly, we hypothesized that these effects may be mediated through independent influences on tau deposition and the relationship of tau with FDG metabolism.

Analyze the association of APOE ?4 and education with regional tau deposition and the impact of tau on FDG metabolism in older adults.

We identified 325 individuals 65 years old and over (53% male, 90% cognitively unimpaired) from the population-based Mayo Clinic Study of Aging who underwent amyloid (PiB-PET), tau (AV1451-PET), and FDG-PET neuroimaging and APOE allele typing.  Regional tau burden and FDG metabolism was estimated for 43 atlas-defined regions.  Association tests utilized APOE ?4 status (presence vs. absence) and education (total years; high vs. low using a cutoff of 14 years) as predictors and regional tau burden and regional FDG/tau ratio as outcomes.  Age, sex, and composite vascular risk were used as primary covariates, with global amyloid burden as an additional covariate for secondary analyses.

Although APOE ?4 was associated with higher tau (p<0.001, Cohen’s d=0.42) and lower FDG/tau ratio (p=0.01, d=0.33) in the entorhinal cortex in the population, these associations were completely attenuated after additionally controlling for amyloid burden.  We identified no significant effects of education on any phenotype.  Global amyloid burden was the strongest driver of tau levels in AD-signature regions.  Age and regional tau were the strongest drivers of hypometabolism in most regions.

In this study, we identified no independent effect of APOE ?4 or education on tau accumulation.  Our results suggest that tau deposition is largely related to amyloid burden, and that effects of APOE ?4 and education on cognitive impairment are likely not mediated by direct effects on tau pathophysiology.

Authors/Disclosures
Vijay K. Ramanan, MD, PhD (Mayo Clinic)
PRESENTER
The institution of Dr. Ramanan has received research support from the National Institutes of Health. The institution of Dr. Ramanan has received research support from the Mangurian Foundation for Lewy Body Disease Research. The institution of Dr. Ramanan has received research support from as part of clinical trials sponsored by the Alzheimer's Association, Eisai, the Alzheimer's Treatment and Research Institute at USC, and Transposon Therapeutics, Inc.. The institution of Dr. Ramanan has received research support from Medscape. The institution of Dr. Ramanan has received research support from Expert Perspectives in Medicine. Dr. Ramanan has received personal compensation in the range of $500-$4,999 for serving as a Conference Speaker/Organizer (Honoraria) with AANI.
Anna Castillo Anna Castillo has nothing to disclose.
David S. Knopman, MD, FAAN (Mayo Clinic) Dr. Knopman has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for DIAN TU study. The institution of Dr. Knopman has received research support from NIH.
Val J. Lowe, MD (Mayo Clinic) Dr. Lowe has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for AVID Radiopharmaceutical. Dr. Lowe has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Eisai Inc. The institution of Dr. Lowe has received research support from AVID Radiopharmaceuticals.
Michelle M. Mielke, PhD (Wake Forest University School of Medicine) Dr. Mielke has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Merck. Dr. Mielke has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Eisai. Dr. Mielke has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Eli Lilly. Dr. Mielke has received personal compensation in the range of $500-$4,999 for serving as a Consultant for LabCorp. Dr. Mielke has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Roche. Dr. Mielke has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Siemens Healthineers. Dr. Mielke has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Sunbird Bio. Dr. Mielke has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Eisai. Dr. Mielke has received personal compensation in the range of $5,000-$9,999 for serving on a Speakers Bureau for Roche. Dr. Mielke has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Novo Nordisk.
Ronald C. Petersen, MD, PhD, FAAN (Mayo Clinic) Dr. Petersen has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Roche. Dr. Petersen has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Genentech. Dr. Petersen has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Eli Lilly and Co.. Dr. Petersen has received personal compensation in the range of $0-$499 for serving as a Consultant for Eisai, Inc.. Dr. Petersen has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Novo Nordisk. Dr. Petersen has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Novartis. Dr. Petersen has received publishing royalties from a publication relating to health care. Dr. Petersen has received publishing royalties from a publication relating to health care. Dr. Petersen has received publishing royalties from a publication relating to health care. Dr. Petersen has a non-compensated relationship as a Board of Directors with American Brain Foundation that is relevant to AAN interests or activities.
Clifford R. Jack, Jr., MD (Mayo Clinic) The institution of Dr. Jack has received research support from NIH. The institution of Dr. Jack has received research support from Alexander Family Alzheimer's Disease Research Professorship of the Mayo Clinic.
Prashanthi Vemuri, PhD (Mayo Clinic) The institution of Dr. Vemuri has received research support from NIH.